Plain-English translation of NCT07214987 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing a combination of three drugs — toripalimab (an immune-boosting medication), , and (two chemotherapy drugs) — given together as initial treatment for people with advanced head and neck cancer. The goal is to see whether this medication combination can shrink tumors before patients receive surgery or radiation therapy, and to understand how safe the treatment is.
While the immune-boosting medication toripalimab is already approved for other types of head and neck cancer, it has not yet been tested in combination with these two chemotherapy drugs for the specific type of advanced head and neck cancer in this trial. Researchers want to see if this new combination might help more patients and work better than existing options.
You likely qualify if…
You likely don't qualify if…
If you join this trial, you would receive the medication combination once every three weeks for up to three treatment cycles (about 9 weeks total). Each treatment day, you would receive three infusions through an IV — the immune-boosting medication first, followed by the two chemotherapy drugs — with each infusion taking 1 to 3 hours. After completing the trial treatment, you would be monitored and followed by your care team for two years to see how you respond and to watch for any side effects.
AI-generated summary from trial data · Jul 21, 2026 · Not medical advice
United States